Bone Infections

The fluoroquinolones have had a major impact on the oral management of Gram-negative bacillary and polymicrobial osteomyelitis [74,75], achieving cure rates of between 65 and 95%—lower in infections caused by P. aeruginosa—in a disease previously requiring prolonged parenteral combination therapy. In staphylococcal osteomyelitis, notably that caused by MRSA and coagulase-nega-tive staphylococci, fluoroquinolones should not be used routinely [16], although results with original fluoroquinolones (e.g., pefloxacin) plus rifampicin suggested potential for combination therapy [76].

0 0

Post a comment